文献速递结核与非结核分枝杆菌

结核病预防性治疗:超短程方案试验的科学与伦理考量

Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.
PubMed 文献 · Lancet Infect Dis · 2025-03-22

预防性治疗是消除结核病的关键,但现有1-4个月方案绝对时长仍长、接受度低。超短程方案(短于2周)的疗效尚待探索,其公共卫生获益可能优于标准方案。本文讨论超短程结核病预防性治疗试验的科学与伦理考量,认为需设无治疗或延迟治疗对照以刻画不同时长与疗效的关系,并在适当风险缓解措施下伦理可接受。

要点

  • 现有1-4个月预防性治疗方案较6-9个月标准治疗已大幅缩短,但绝对时长仍长且接受度低。
  • 超短程方案(短于2周)的疗效尚未探索,其公共卫生结局可能优于标准治疗。
  • 超短程方案最佳时长无法通过经典两臂非劣效试验探索,需随机分配部分参与者至无治疗或延迟治疗组。

核心结论

  • 超短程结核病预防性治疗试验对于确定疗效与接受度的最佳权衡是必要的,在采取适当风险缓解措施(包括仔细监测活动性疾病发生)的前提下伦理可接受。

研究设计与样本

  • 本文为Personal View,讨论超短程结核病预防性治疗试验的科学与伦理考量,未报告系统检索范围或样本量。

主要发现

  • 使用非劣效设计的缩短疗程试验已促成1-4个月有效方案的实施,较先前6-9个月标准治疗大幅改进,但鉴于潜在毒性和多数个体极低的基线疾病风险,仍远过长。
  • 超短程方案(短于2周)的疗效尚待探索,即使其疗效低于标准治疗,也可能实现最佳公共卫生结局,因为更高接受度可能带来更高人群 uptake,并可能避免更多结核病病例。
  • 超短程方案的最佳时长无法通过经典两臂非劣效试验探索,需刻画不同时长与疗效的关系,要求部分参与者被随机分配至无治疗或延迟治疗组,以刻画最短方案所避免的结核病病例数。

临床怎么用

  • 作者认为,此类试验对于确定疗效与接受度的最佳权衡是必要的,且在采取适当风险缓解措施(包括仔细监测活动性疾病发生)的前提下伦理可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preventive therapy remains key to the elimination of tuberculosis and is typically offered to people with presumptive Mycobacterium tuberculosis infection to prevent active disease. Although the duration of tuberculosis preventive therapy has been reduced substantially over time, it remains long in absolute terms, and uptake remains low. Treatment-shortening trials using non-inferiority designs have so far led to the implementation of effective regimens of 1-4 months' duration. Such regimens are a substantial improvement on the previous 6-9 months' duration standard of care but still far too long given potential toxicity and the very low baseline risk of disease for most individuals. The efficacy of even shorter tuberculosis preventive therapy regimens, including ultra-short regimens shorter than 2 weeks' duration, is yet to be explored, but optimal public health outcomes might be achieved even if the efficacy of such regimens is lower than that of the standard of care. Greater acceptability could lead to higher population uptake, and, potentially, to more cases of tuberculosis avoided. Nonetheless, the optimal duration of ultra-short tuberculosis preventive therapy regimens cannot be explored through classic two-arm non-inferiority trials. Instead, the relationship between different durations and efficacy of tuberculosis preventive therapy will need to be characterised, requiring some participants to be randomly assigned to no (or delayed) therapy in order to characterise the number of tuberculosis cases averted by the shortest options. We argue that such trials are needed to identify the optimal trade-off between efficacy and acceptability and would be ethically acceptable provided there were appropriate risk mitigation measures for participants, including careful monitoring for the development of active disease. In this Personal View, we discuss some of the scientific and ethical considerations around the investigation of ultra-short-course preventive therapy for tuberculosis.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Walker TM, Watson JA, Moore DAJ, et al. Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens. Lancet Infect Dis. 2025. PMID: 40127669. doi:10.1016/S1473-3099(25)00083-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。